| 摘要 |
The invention provides methods for inhibiting psychostimulant-induced or nicotine-induced craving of additional psychostimulants (e.g., cocaine or amphetamine) or nicotine. In these methods, D1-like (dopamine receptor) antagonists or agonists selected from the group consisting of SCH-39166, SCH23388, SCH-23390, A-69024, bulbocapnine, (+)butaclamol HCI, fluphenazine HCI, cis-(Z)-flupenthixol, fluspirilene, haloperidol, SCH-12679, SKF-83566, thioridazine HCI, thiothixene HCI, trifluoperazine 2HCI, trifluperidol HCI, A86929, skf-81297, SKF-38393, R(-)-N-allylnorapomorphine HBr, R-(-)-apomorphine HCI, R-(+)-6-bromo-APB, R-(+)-6-chloro-ABP, (+)-SKF-82958, Pergolide methanesulfonate, and SKF-77434 are administed to a patient dependent on psychostimulant drugs or nicotine and therefore susceptible to, or suffering from, such a craving. Also disclosed is an animal model system useful for measuring the ability of test compounds to inhibit psychostimulant-induced or nicotine-induced cravings in humans.
|
